PF-06835375 ( DrugBank: - )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1
49	全身性エリテマトーデス	1
63	特発性血小板減少性紫斑病	2

46. 悪性関節リウマチ

臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03334851 (ClinicalTrials.gov)	November 17, 2017	3/11/2017	Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis	A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS	Systemic Lupus Erythematosus;Rheumatoid Arthritis	Drug: PF-06835375;Drug: Placebo	Pfizer	NULL	Completed	18 Years	70 Years	All	75	Phase 1	United States;Puerto Rico

49. 全身性エリテマトーデス

臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03334851 (ClinicalTrials.gov)	November 17, 2017	3/11/2017	Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis	A PHASE 1, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS	Systemic Lupus Erythematosus;Rheumatoid Arthritis	Drug: PF-06835375;Drug: Placebo	Pfizer	NULL	Completed	18 Years	70 Years	All	75	Phase 1	United States;Puerto Rico

63. 特発性血小板減少性紫斑病

臨床試験数 : 363 / 薬物数 : 212 - (DrugBank : 43) / 標的遺伝子数 : 47 - 標的パスウェイ数 : 138

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-002897-19-HU (EUCTR)	02/03/2022	23/12/2021	A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375 in adult participants with Immune thrombocytopenia, a disorder in which there is a reduced amount of platelets in the blood stream which are important for blood to clot normally	AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA - A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375	Primary immune thrombocytopenia MedDRA version: 23.0;Level: LLT;Classification code 10083843;Term: Primary immune thrombocytopenia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Product Name: PF-06835375 Product Code: PF-06835375 INN or Proposed INN: not available Other descriptive name: PF-06835375	Pfizer Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	United States;Czechia;Hungary;Canada;Poland;Australia
2	NCT05070845 (ClinicalTrials.gov)	January 31, 2022	27/9/2021	Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia	AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA	Primary Immune Thrombocytopenia	Biological: PF-06835375	Pfizer	NULL	Not yet recruiting	18 Years	70 Years	All	40	Phase 2	United States;Poland